These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 18807035)
21. Induction of potent antitumor immunity by in situ targeting of intratumoral DCs. Furumoto K; Soares L; Engleman EG; Merad M J Clin Invest; 2004 Mar; 113(5):774-83. PubMed ID: 14991076 [TBL] [Abstract][Full Text] [Related]
22. BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells. Huang S; Sinicrope FA Cancer Res; 2008 Apr; 68(8):2944-51. PubMed ID: 18413764 [TBL] [Abstract][Full Text] [Related]
23. Anti-idiotype antibody induced cellular immunity in mice transgenic for human carcinoembryonic antigen. Saha A; Chatterjee SK; Foon KA; Bhattacharya-Chatterjee M Immunology; 2006 Aug; 118(4):483-96. PubMed ID: 16895556 [TBL] [Abstract][Full Text] [Related]
24. A multifunctional chimeric chaperone serves as a novel immune modulator inducing therapeutic antitumor immunity. Yu X; Guo C; Yi H; Qian J; Fisher PB; Subjeck JR; Wang XY Cancer Res; 2013 Apr; 73(7):2093-103. PubMed ID: 23333935 [TBL] [Abstract][Full Text] [Related]
25. Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins. Tagscherer KE; Fassl A; Campos B; Farhadi M; Kraemer A; Böck BC; Macher-Goeppinger S; Radlwimmer B; Wiestler OD; Herold-Mende C; Roth W Oncogene; 2008 Nov; 27(52):6646-56. PubMed ID: 18663354 [TBL] [Abstract][Full Text] [Related]
26. Central nervous system tumor immunity generated by a recombinant listeria monocytogenes vaccine targeting tyrosinase related protein-2 and real-time imaging of intracranial tumor burden. Prins RM; Bruhn KW; Craft N; Lin JW; Kim CH; Odesa SK; Miller JF; Liau LM Neurosurgery; 2006 Jan; 58(1):169-78; discussion 169-78. PubMed ID: 16385341 [TBL] [Abstract][Full Text] [Related]
27. Restoring cancer's death sentence. Letai A Cancer Cell; 2006 Nov; 10(5):343-5. PubMed ID: 17097553 [TBL] [Abstract][Full Text] [Related]
28. Fusion proteins of Hsp70 with tumor-associated antigen acting as a potent tumor vaccine and the C-terminal peptide-binding domain of Hsp70 being essential in inducing antigen-independent anti-tumor response in vivo. Zhang H; Huang W Cell Stress Chaperones; 2006; 11(3):216-26. PubMed ID: 17009594 [TBL] [Abstract][Full Text] [Related]
29. Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737. Oakes SR; Vaillant F; Lim E; Lee L; Breslin K; Feleppa F; Deb S; Ritchie ME; Takano E; Ward T; Fox SB; Generali D; Smyth GK; Strasser A; Huang DC; Visvader JE; Lindeman GJ Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2766-71. PubMed ID: 21768359 [TBL] [Abstract][Full Text] [Related]
30. Resistance of cancers to immunologic cytotoxicity and adoptive immunotherapy via X-linked inhibitor of apoptosis protein expression and coexisting defects in mitochondrial death signaling. Ravi R; Fuchs EJ; Jain A; Pham V; Yoshimura K; Prouser T; Jalla S; Zhou X; Garrett-Mayer E; Kaufmann SH; Schulick RD; Pardoll DM; Bedi A Cancer Res; 2006 Feb; 66(3):1730-9. PubMed ID: 16452233 [TBL] [Abstract][Full Text] [Related]
31. Bcl-2 inhibitors reduce steroid-insensitive airway inflammation. Tian BP; Xia LX; Bao ZQ; Zhang H; Xu ZW; Mao YY; Cao C; Che LQ; Liu JK; Li W; Chen ZH; Ying S; Shen HH J Allergy Clin Immunol; 2017 Aug; 140(2):418-430. PubMed ID: 28043871 [TBL] [Abstract][Full Text] [Related]
32. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors. Li B; VanRoey M; Wang C; Chen TH; Korman A; Jooss K Clin Cancer Res; 2009 Mar; 15(5):1623-34. PubMed ID: 19208793 [TBL] [Abstract][Full Text] [Related]
33. Combining CAR T cells and the Bcl-2 family apoptosis inhibitor ABT-737 for treating B-cell malignancy. Karlsson H; Lindqvist AC; Fransson M; Paul-Wetterberg G; Nilsson B; Essand M; Nilsson K; Frisk P; Jernberg-Wiklund H; Loskog A Cancer Gene Ther; 2013 Jul; 20(7):386-93. PubMed ID: 23788110 [TBL] [Abstract][Full Text] [Related]
34. Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells. Tsao T; Shi Y; Kornblau S; Lu H; Konoplev S; Antony A; Ruvolo V; Qiu YH; Zhang N; Coombes KR; Andreeff M; Kojima K; Konopleva M Ann Hematol; 2012 Dec; 91(12):1861-70. PubMed ID: 22893484 [TBL] [Abstract][Full Text] [Related]
35. Anti-allergic and anti-inflammatory effects of the Bcl-2 inhibitor ABT-737 on experimental allergic rhinitis models. Kim HY; Jeong HJ; Kim HM Eur J Pharmacol; 2018 Aug; 833():34-43. PubMed ID: 29856968 [TBL] [Abstract][Full Text] [Related]
36. Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells. Mérino D; Khaw SL; Glaser SP; Anderson DJ; Belmont LD; Wong C; Yue P; Robati M; Phipson B; Fairlie WD; Lee EF; Campbell KJ; Vandenberg CJ; Cory S; Roberts AW; Ludlam MJ; Huang DC; Bouillet P Blood; 2012 Jun; 119(24):5807-16. PubMed ID: 22538851 [TBL] [Abstract][Full Text] [Related]
37. Immunization against endogenous retroviral tumor-associated antigens. Kershaw MH; Hsu C; Mondesire W; Parker LL; Wang G; Overwijk WW; Lapointe R; Yang JC; Wang RF; Restifo NP; Hwu P Cancer Res; 2001 Nov; 61(21):7920-4. PubMed ID: 11691813 [TBL] [Abstract][Full Text] [Related]
38. HSP90 inhibitor (NVP-AUY922) enhances the anti-cancer effect of BCL-2 inhibitor (ABT-737) in small cell lung cancer expressing BCL-2. Yang H; Lee MH; Park I; Jeon H; Choi J; Seo S; Kim SW; Koh GY; Park KS; Lee DH Cancer Lett; 2017 Dec; 411():19-26. PubMed ID: 28987383 [TBL] [Abstract][Full Text] [Related]
39. Celecoxib-induced apoptosis is enhanced by ABT-737 and by inhibition of autophagy in human colorectal cancer cells. Huang S; Sinicrope FA Autophagy; 2010 Feb; 6(2):256-69. PubMed ID: 20104024 [TBL] [Abstract][Full Text] [Related]
40. ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms. Kuroda J; Kimura S; Andreeff M; Ashihara E; Kamitsuji Y; Yokota A; Kawata E; Takeuchi M; Tanaka R; Murotani Y; Matsumoto Y; Tanaka H; Strasser A; Taniwaki M; Maekawa T Br J Haematol; 2008 Jan; 140(2):181-90. PubMed ID: 18028486 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]